Dr. Reddy's gets FDA nod for XeglyzeDr. Reddy's Xeglyze is indicated for patients with a head lice infestation. Jazz Pharmaceuticals obtains FDA blessing for XywavJazz Pharmaceuticals' Xywav is indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy. FDA approves new indication for Grünenthal, Averitas' Qutenza Grünenthal and its U.S. subsidiary, Averitas Pharma’s Qutenza (capsaicin), is the first and only treatment of its kind to deliver prescription-strength capsaicin directly into the skin. Mylan, Upjohn unveil branding for Viatris Viatris’ platform will provide a unique global healthcare gateway that will offer partners ready access to more markets and patients worldwide. Xeris debuts Gvoke HypoPen Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle. FDA approves Rukobia for HIV ViiV Healthcare's Rukobia is a treatment for patients with multidrug-resistant HIV infections. Upsher-Smith offers help to people with migraines during Migraine Month Upsher-Smith's Access Pathways Program offers patient savings and support services for patients who need migraine medications. Novartis receives FDA nod for new indication of Cosentyx The indication to treat non-radiographic axial spondyloarthritis is the fourth FDA-approved indication for Novartis’ Cosentyx. Abbott gets FDA clearance for FreeStyle Libre 2 Abbott's FreeStyle Libre 2 continuous glucose monitoring system does not require fingersticks. Dr. Reddy's inks licensing deal with Gilead for remdesivir Dr. Reddy's will manufacture remdesivir, Gilead's investigational antiviral therapy used to treat COVID-19. First Previous 27 28 29 30 31 Next Last
